WuXi AppTec (600425.SH/2359.HK): China largest pharma CRO/CDMO with $5B+ revenue, 40K+ employees globally. Services include drug discovery, preclinical, clinical trials (CRO), manufacturing (CDMO), cell/gene therapy (WuXi ATU), and testing. HQ in Shanghai, operations in US, Europe, Asia. Serves top 20 global pharma companies. Recently impacted by US Biosecure Act concerns.
read more..